TokenPost·
Rapport Therapeutics Shares Close 2.7% Higher on Phase 2 Results Day
2.7%
share price gain
Monday’s 3.74% gain came before the announcement. RAP-219 met the primary and secondary endpoints in a three-week trial.
More news
- TokenPostPump.fun Drops 4.40% in One Hour to $0.004494 on Binance
- TokenPostMorpho Falls 4.33% in One Hour to $2.39 on Binance Spot
- TokenPostTiny Transfers Dominated RLUSD-Coded Payments on XRP Ledger
- TokenPostBitcoin’s 30-Day Implied Volatility Tops 14-Day Realized Reading
- TokenPostBitcoin Stalled Below $87,000 to $87,800 Resistance Band
- TokenPostSolana Falls 2.36% in One Hour to $105 in Oct. 20 Trading